Vaxart to Host First Quarter 2024 Business Update and Financial Results Conference Call on May 13
Vaxart, Inc. (NASDAQ: VXRT) will host a conference call on May 13, 2024, to provide a business update and report financial results for the first quarter ending March 31, 2024. Investors can access the conference call online or by phone, and submit questions in advance. A replay will be available on the company's website.
- None.
- None.
Conference call to begin at 4:30 p.m. ET
SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the first quarter ended March 31, 2024 after the market close on Monday, May 13, 2024. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET.
The conference call can be accessed using the following information:
Webcast: Click here
Date: Monday, May 13, 2024 – 4:30 p.m. ET
Domestic: (877) 407-0832
International: (201) 689-8433
Conference ID: 13745591
Investors may submit written questions in advance of the conference call to ir@vaxart.com.
A replay of the webcast will be available on the Company’s website at www.vaxart.com following the conclusion of the event.
About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus, and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
| Contacts | ||
| Vaxart Media Relations: Mark Herr Vaxart, Inc. mherr@vaxart.com (203) 517-8957 | Investor Relations: Andrew Blazier FINN Partners IR@vaxart.com (646) 871-8486 | |
FAQ
When will Vaxart host the conference call for the first quarter 2024 business update and financial results?
What will be discussed during the conference call?
How can investors access the conference call?
Can investors submit questions in advance of the conference call?
Where can investors find a replay of the webcast after the conference call?
